These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12666126)

  • 1. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease.
    Scoazec JY; Krolak-Salmon P; Casez O; Besson G; Thobois S; Kopp N; Perret-Liaudet A; Streichenberger N
    Ann Neurol; 2003 Apr; 53(4):546-7. PubMed ID: 12666126
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine].
    Furukawa H; Takahashi M; Nakajima M; Yamada T
    Nihon Rinsho; 2002 Aug; 60(8):1649-57. PubMed ID: 12187766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease.
    Nakajima M; Yamada T; Kusuhara T; Furukawa H; Takahashi M; Yamauchi A; Kataoka Y
    Dement Geriatr Cogn Disord; 2004; 17(3):158-63. PubMed ID: 14739538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
    Haïk S; Brandel JP; Salomon D; Sazdovitch V; Delasnerie-Lauprêtre N; Laplanche JL; Faucheux BA; Soubrié C; Boher E; Belorgey C; Hauw JJ; Alpérovitch A
    Neurology; 2004 Dec; 63(12):2413-5. PubMed ID: 15623716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Old drugs to treat new variant Creutzfeldt-Jakob disease.
    Love R
    Lancet; 2001 Aug; 358(9281):563. PubMed ID: 11520533
    [No Abstract]   [Full Text] [Related]  

  • 6. Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease.
    Satoh K; Shirabe S; Eguchi K; Yamauchi A; Kataoka Y; Niwa M; Nishida N; Katamine S
    Cell Mol Neurobiol; 2004 Dec; 24(6):873-5. PubMed ID: 15672687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Creutzfeldt-Jakob disease].
    Nanri Y; Kuroda Y
    Nihon Rinsho; 2004 Jan; 62 Suppl():244-7. PubMed ID: 15011358
    [No Abstract]   [Full Text] [Related]  

  • 8. Drugs for malaria and psychosis may offer hope to people with CJD.
    Josefson D
    BMJ; 2001 Aug; 323(7310):416. PubMed ID: 11520828
    [No Abstract]   [Full Text] [Related]  

  • 9. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model.
    Collins SJ; Lewis V; Brazier M; Hill AF; Fletcher A; Masters CL
    Ann Neurol; 2002 Oct; 52(4):503-6. PubMed ID: 12325081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
    Benito-León J
    Neurology; 2005 May; 64(10):1824; author reply 1824. PubMed ID: 15911834
    [No Abstract]   [Full Text] [Related]  

  • 11. Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine.
    Martínez-Lage JF; Rábano A; Bermejo J; Martínez Pérez M; Guerrero MC; Contreras MA; Lunar A
    Surg Neurol; 2005 Dec; 64(6):542-5, discussion 545. PubMed ID: 16293480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation].
    Kobayashi Y; Hirata K; Tanaka H; Yamada T
    Rinsho Shinkeigaku; 2003 Jul; 43(7):403-8. PubMed ID: 14582366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.
    Geschwind MD; Kuo AL; Wong KS; Haman A; Devereux G; Raudabaugh BJ; Johnson DY; Torres-Chae CC; Finley R; Garcia P; Thai JN; Cheng HQ; Neuhaus JM; Forner SA; Duncan JL; Possin KL; Dearmond SJ; Prusiner SB; Miller BL
    Neurology; 2013 Dec; 81(23):2015-23. PubMed ID: 24122181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinacrine in possible or probable CJD: if you had suspected CJD would you be indifferent between placebo and quinacrine?
    Braunholtz D; Harris J
    BMJ; 2002 Jan; 324(7331):239. PubMed ID: 11809660
    [No Abstract]   [Full Text] [Related]  

  • 15. Quinacrine in possible or probable CJD: it is blinded investigators, not patients, who must be in equipoise over treatment.
    Cooper E
    BMJ; 2002 Jan; 324(7331):239. PubMed ID: 11831208
    [No Abstract]   [Full Text] [Related]  

  • 16. Compassion comes before science.
    New Sci; 2001 Aug; 171(2304):3. PubMed ID: 11838483
    [No Abstract]   [Full Text] [Related]  

  • 17. Fast-track CJD trial: two years late, but not derailed.
    Lancet Neurol; 2004 May; 3(5):257. PubMed ID: 15099535
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid drug trial offers hope to CJD patients.
    Giles J
    Nature; 2003 Dec; 426(6966):487. PubMed ID: 14654808
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease.
    Parchi P; Castellani R; Capellari S; Ghetti B; Young K; Chen SG; Farlow M; Dickson DW; Sima AA; Trojanowski JQ; Petersen RB; Gambetti P
    Ann Neurol; 1996 Jun; 39(6):767-78. PubMed ID: 8651649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CJD researchers close to agreeing plans for first clinical trial. Arguments have marred discussions about protocol design, prompting allegations of "academic jealousy".
    Butcher J; Brown H
    Lancet; 2004 Apr; 363(9416):1201. PubMed ID: 15083817
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.